Pelacarsen, an experimental medicine designed to lower lipoprotein(a), did not meet the primary cardiovascular-outcome goal in a large Phase 3 trial, Novartis announced on September 4, 2026.
The Lp(a)HORIZON study enrolled 8,323 people with elevated lipoprotein(a), known as Lp(a), and established cardiovascular disease. Participants were already receiving standard care.
What the pelacarsen trial tested
The randomised, double-blind, placebo-controlled trial examined whether pelacarsen could reduce a composite of cardiovascular death, non-fatal heart attack, non-fatal stroke and urgent coronary revascularisation requiring hospitalisation.
Novartis said the medicine substantially lowered Lp(a), consistent with earlier studies, but the reduction did not translate into a statistically significant improvement in the primary clinical endpoint compared with placebo.
Why Lp(a) is important
Lp(a) is an inherited cardiovascular risk factor. Its level is largely genetically determined and is generally much less responsive to diet or exercise than conventional LDL cholesterol.
High levels are associated with plaque build-up, inflammation and cardiovascular events. The trial was closely watched because it directly tested whether lowering this biomarker would reduce serious outcomes in people already at high risk.
A negative topline result needs full data
The company’s announcement presented topline findings. Full results are expected at a future medical meeting, where researchers can examine subgroups, safety, adherence, achieved Lp(a) reductions and individual components of the primary endpoint.
A missed primary endpoint means the trial did not demonstrate its planned overall benefit under the prespecified statistical analysis. It does not prove that Lp(a) is irrelevant, nor does it establish that other medicines using different mechanisms will fail.
What patients should understand
Pelacarsen remains experimental and is not a substitute for approved cardiovascular treatment. Patients should continue prescribed medicines and discuss personal risk factors with their clinicians.
The result also does not change the established importance of blood-pressure control, smoking cessation, diabetes management and treatment of LDL cholesterol when medically indicated.
Implications for drug development
Other companies are studying different approaches to lowering Lp(a). Regulators and researchers will use the full Lp(a)HORIZON data to refine future trial design and understand whether patient selection, treatment duration or biological mechanism matters.
Novartis licensed pelacarsen from Ionis Pharmaceuticals. Both companies acknowledged that biomarker reduction did not produce the hoped-for cardiovascular benefit in this trial.
The central verified finding is therefore narrow but important: Lp(a) fell, while the primary outcome did not reach statistical significance.
